Jetstar to Charge for Overhead Cabin Bags From February 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Heidelberg, Germany, March 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company's AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.
Poster Presentation
Abstract: Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)
Session: PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Monday, April 16, 2018 1:00 PM - 5:00 PM (CT)
Location: McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL
Full abstract of the presentation can be accessed on the AACR website at www.aacr.org
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
